- Help4HD discusses SAGE-718 
- TEVA gathers more data about AUSTEDO 
- The state of PolyQ research: a review of the landscape 

Help4HD discusses SAGE-718 

Cognitive changes are a frequent early symptom of HD that can have major impacts on quality of life. Cognitive decline can affect numerous pieces of daily living like cooking a meal, doing mental math, using transportation, or managing finances. Recently on the Help4HD podcast, host Lauren Holder was joined by Jennifer Petrillo Billet from Sage therapeutics to talk about the significance of cognition in HD and the importance of patient-reported outcomes to track cognitive change over time. The pair also discuss SAGE-718, a drug taken by mouth that is aimed at addressing cognitive decline in HD and is currently being tested in clinical trials. To listen to the full episode, click here. 

TEVA gathers more data about AUSTEDO 

This week, TEVA announced the results of their Phase 4 START study, which assessed real-world effectiveness, safety, adherence, and satisfaction with 4-week titration kits for AUSTEDO. The kits had both a strong patient satisfaction rate and effectiveness profile and allow people with HD who are taking AUSTEDO to adjust their medication based on their individual HD chorea symptoms. To read the full press release, click here.  

The state of PolyQ research: a review of the landscape 

HD is one of nine identified polyQ disorders—diseases that involve expansion of CAG repeats. These distinct diseases have some commonalities in the ways they present, such as neuronal damage and functional changes in day-to-day abilities. CAS, a division of the American Chemical Society, recently reported on the state of the HD and larger PolyQ research fields. The article assesses trends in publications, identifies challenges in treating HD and related disease, and surveys therapeutic strategies being investigated to treat these conditions. The article is aimed at a research and medical audience, but the findings indicate that HD publications have increased in recent years, a positive sign that therapeutic discoveries are moving closer to treatments for HD and PolyQ diseases. Read the full article here.